AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22739327 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 15
Study 21535999 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of hydrocortisone
Number of subjects: 95
Study 21535999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 21535999 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of hydrocortisone after learning
Number of subjects: 95
Study 21067020 — intervention group
Group type: EXPERIMENTAL
Intervention: Over and over continuous suturing (Group-1)
Number of subjects: 100
Study 21067020 — intervention group
Group type: COMPARATOR
Intervention: Continuous inverting sutures (Group-2)
Number of subjects: 100
Study 16490643 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (1 mEq/kg)
Number of subjects: 874
Study 16490643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 874
Study 16490643 — intervention group
Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 874
Study 15362678 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone intravenously before surgery
Number of subjects: 30
Study 15362678 — intervention group
Group type: COMPARATOR
Intervention: No glucocorticoid therapy for thirty days before surgery (Control)
Number of subjects: 30
Study 10950012 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine (Group A)
Number of subjects: 30
Study 10950012 — intervention group
Group type: COMPARATOR
Intervention: Physiologic saline (Group B)
Number of subjects: 30
Study 9624373 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTA) injection (4 units total: 2 units in each nasal cavity for middle and inferior turbinate)
Number of subjects: 0
Study 9624373 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 0
Study 8172263 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser photocoagulation
Number of subjects: 14
Study 8172263 — intervention group
Group type: COMPARATOR
Intervention: Argon laser photocoagulation
Number of subjects: 14
Study 3414581 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg zinc/d
Number of subjects: 103
Study 3414581 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg Zn/d
Number of subjects: 103
Study 3414581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 3414581 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (including vitamin-mineral supplement)
Number of subjects: 103
Study 31639246 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin therapy
Number of subjects: 30
Study 31639246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 28922590 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-126 25 mg
Number of subjects: 157
Study 28922590 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-126 75 mg
Number of subjects: 157
Study 28922590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study 28922590 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-126
Number of subjects: 157
Study 26866955 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted intervention with 3 individual counseling sessions
Number of subjects: 112
Study 26866955 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted intervention
Number of subjects: 112
Study 26866955 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving sexual health advice as part of regular HIV care
Number of subjects: 112
Study 26866955 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 112
Study 24432872 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 8255
Study 24432872 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin/VKA
Number of subjects: 8255
Study 22146084 — intervention group
Group type: EXPERIMENTAL
Intervention: Iranian version of the Female Sexual Function Index (IV-FSFI)
Number of subjects: 448
Study 22146084 — intervention group
Group type: EXPERIMENTAL
Intervention: IV-FSFI
Number of subjects: 448
Study 19556043 — intervention group
Group type: EXPERIMENTAL
Intervention: Total urine protein level of 3.5 g/d
Number of subjects: 1608
Study 19556043 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine total protein level of 3.5 g/d or greater at baseline
Number of subjects: 1608
Study 19556043 — intervention group
Group type: EXPERIMENTAL
Intervention: Other signs and symptoms of nephrotic syndrome at baseline
Number of subjects: 1608
Study 19556043 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression of kidney disease during follow‐up
Number of subjects: 1608
Study 19556043 — intervention group
Group type: EXPERIMENTAL
Intervention: Measures of proteinuria
Number of subjects: 1608
Study 19556043 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold levels for nephrotic‐range proteinuria and albuminuria
Number of subjects: 1608
Study 16783598 — intervention group
Group type: EXPERIMENTAL
Intervention: CT imaging from the CT Image Library (CTIL)
Number of subjects: 17308
Study 15099879 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopic rollerball electrocoagulation (RBE)
Number of subjects: 137
Study 15099879 — intervention group
Group type: COMPARATOR
Intervention: Uterine balloon thermal ablation (Thermachoice)
Number of subjects: 137
Study 12397539 — intervention group
Group type: EXPERIMENTAL
Intervention: R-FCM (Rituximab + Fludarabine-Cyclophosphamide-Mitoxantrone); Rituximab 375 mg/m2 one day before FCM
Number of subjects: 147
Study 12397539 — intervention group
Group type: COMPARATOR
Intervention: FCM (Fludarabine-Cyclophosphamide-Mitoxantrone) alone
Number of subjects: 147
Study 12397539 — intervention group
Group type: EXPERIMENTAL
Intervention: R-FCM
Number of subjects: 147
Study 12397539 — intervention group
Group type: COMPARATOR
Intervention: FCM
Number of subjects: 147
Study 10211309 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinyl palmitate (300,000 I.U. daily for 1 month)
Number of subjects: 25
Study 10211309 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 25
Study 7796647 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU mixed with Isovist‐300 injected into the pelvic retroperitoneal space
Number of subjects: 0
Study 7796647 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified what treatment was used)
Number of subjects: 0
Study 2196145 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 200 mg
Number of subjects: 10
Study 2196145 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg
Number of subjects: 10
Study 2196145 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 800 mg
Number of subjects: 10
Study 2196145 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 1200 mg
Number of subjects: 10
Study 2196145 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 24 mg/kg (in monkeys)
Number of subjects: 10
Study 2196145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 643471 — intervention group
Group type: EXPERIMENTAL
Intervention: Subliminal message 'masculine'
Number of subjects: 100
Study 643471 — intervention group
Group type: EXPERIMENTAL
Intervention: Subliminal message 'feminine'
Number of subjects: 100
Study 643471 — intervention group
Group type: EXPERIMENTAL
Intervention: Subliminal flash of white light
Number of subjects: 100
Study 643471 — intervention group
Group type: COMPARATOR
Intervention: No further stimulation (Control)
Number of subjects: 100
Study 6129874 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine (120 mg/day or higher)
Number of subjects: 0
Study 6129874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6129874 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine (12 mg/day)
Number of subjects: 0
Study 6129874 — intervention group
Group type: EXPERIMENTAL
Intervention: Clemastine (2 mg/day)
Number of subjects: 0
Study 6129874 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 0
Study 6129874 — intervention group
Group type: EXPERIMENTAL
Intervention: Clemastine
Number of subjects: 0
Study 6129874 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine
Number of subjects: 0
Study 30552590 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% articaine
Number of subjects: 180
Study 30552590 — intervention group
Group type: COMPARATOR
Intervention: 2% lignocaine
Number of subjects: 180
Study 28099429 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia at 33 °C for 48 hours after HIE birth
Number of subjects: 50
Study 28099429 — intervention group
Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 50
Study 26070052 — intervention group
Group type: EXPERIMENTAL
Intervention: Earmuffs
Number of subjects: 31
Study 26070052 — intervention group
Group type: COMPARATOR
Intervention: No earmuffs (control)
Number of subjects: 31
Study 24410739 — intervention group
Group type: EXPERIMENTAL
Intervention: Extreme hypo-fractionation (7 × 6.1 Gy)
Number of subjects: 20
Study 22922306 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin infiltration (Icon, pre‐product; DMG, Hamburg)
Number of subjects: 22
Study 22922306 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 22
Study 19204365 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-row rotator cuff repair
Number of subjects: 40
Study 19204365 — intervention group
Group type: COMPARATOR
Intervention: Double-row rotator cuff repair
Number of subjects: 40
Study 17551300 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vinorelbine 60 mg/m2 (dose-escalated to 70 mg/m2 after initial 3 weeks if no unacceptable toxicity)
Number of subjects: 181
Study 17551300 — intervention group
Group type: COMPARATOR
Intervention: Intravenous vinorelbine 30 mg/m2 weekly
Number of subjects: 181
Study 17551300 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vinorelbine for patients with KPS 60-70
Number of subjects: 181
Study 17551300 — intervention group
Group type: COMPARATOR
Intervention: Intravenous vinorelbine for patients with KPS 60-70
Number of subjects: 181
Study 15135024 — intervention group
Group type: EXPERIMENTAL
Intervention: Food reinforcement
Number of subjects: 74
Study 15135024 — intervention group
Group type: EXPERIMENTAL
Intervention: Hedonic ratings for preferred food
Number of subjects: 74
Study 15135024 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-regression models
Number of subjects: 74
Study 12030601 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-gamma (100 microg/m2, sc)
Number of subjects: 13
Study 12030601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 10406818 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE II and ID genotype individuals (n=10)
Number of subjects: 26
Study 10406818 — intervention group
Group type: COMPARATOR
Intervention: ACE DD individuals (n=8)
Number of subjects: 26
Study 10406818 — intervention group
Group type: EXPERIMENTAL
Intervention: apoE3 and E4 individuals (n=15)
Number of subjects: 26
Study 10406818 — intervention group
Group type: COMPARATOR
Intervention: apoE2 individuals (n=3)
Number of subjects: 26
Study 10406818 — intervention group
Group type: EXPERIMENTAL
Intervention: LPL PvuII +/+ individuals (n=4)
Number of subjects: 26
Study 10406818 — intervention group
Group type: COMPARATOR
Intervention: LPL PvuII +/− and −/− individuals (n=14)
Number of subjects: 26
Study 10406818 — intervention group
Group type: EXPERIMENTAL
Intervention: LPL HindIII +/+ and +/− individuals (n=15)
Number of subjects: 26
Study 10406818 — intervention group
Group type: COMPARATOR
Intervention: LPL −/− individuals (n=3)
Number of subjects: 26
Study 10406818 — intervention group
Group type: EXPERIMENTAL
Intervention: LPL PvuII −/− individuals (n=3)
Number of subjects: 26
Study 10406818 — intervention group
Group type: COMPARATOR
Intervention: LPL PvuII +/− and +/+ individuals (n=15)
Number of subjects: 26
Study 7594341 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (group L)
Number of subjects: 0
Study 7594341 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (group R)
Number of subjects: 0
Study 2343792 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiotaped administration of the Situational Competency Test (SCT)
Number of subjects: 0
Study 2343792 — intervention group
Group type: COMPARATOR
Intervention: Written administration of the Situational Competency Test (SCT)
Number of subjects: 0
Study 373450 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipivalyl epinephrine, 0.1%
Number of subjects: 17
Study 373450 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine hydrochloride, 2%
Number of subjects: 17
Study 31337325 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation Therapy
Number of subjects: 80
Study 31337325 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (Referral to PTSD 'Standard Care')
Number of subjects: 80
Study 27702807 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25% fluoride gel
Number of subjects: 46
Study 27702807 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 46
Study 24383912 — intervention group
Group type: COMPARATOR
Intervention: Platform Switching (PS) abutments
Number of subjects: 19
Study 24383912 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Platform Switching (NPS) abutments
Number of subjects: 19
Study 24383912 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PS and NPS)
Number of subjects: 19
Study 24007599 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity prescription + hyper‐corrective night‐time brace
Number of subjects: 135
Study 24007599 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity prescription + postural scoliosis‐specific exercises
Number of subjects: 135
Study 24007599 — intervention group
Group type: COMPARATOR
Intervention: Physical activity prescription (control group)
Number of subjects: 135
Study 24007599 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 135
Study 21285388 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide BID (5 μg for 4 weeks, then 10 μg)
Number of subjects: 354
Study 21285388 — intervention group
Group type: COMPARATOR
Intervention: Premixed insulin aspart 70/30 BID (PIA)
Number of subjects: 354
Study 21285388 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide BID
Number of subjects: 354
Study 19002124 — intervention group
Group type: EXPERIMENTAL
Intervention: Early delivery of stem cells via intramyocardial injection and intracoronary infusion (3-6 weeks after AMI)
Number of subjects: 60
Study 19002124 — intervention group
Group type: EXPERIMENTAL
Intervention: Late delivery of stem cells via intramyocardial injection and intracoronary infusion (3-4 months after AMI)
Number of subjects: 60
Study 16765113 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin with provisional GP IIb/IIIa blockade
Number of subjects: 1558
Study 16765113 — intervention group
Group type: COMPARATOR
Intervention: Heparin and planned GP IIb/IIIa blockade
Number of subjects: 1558
Study 15450560 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass (OPCAB)
Number of subjects: 16505
Study 15450560 — intervention group
Group type: COMPARATOR
Intervention: On-pump coronary artery bypass
Number of subjects: 16505
Study 12140003 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Donepezil administration (5mg/day) for 11+/‐2.6 months
Number of subjects: 25
Study 12140003 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated AD patients)
Number of subjects: 25
Study 10212779 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (CPFX) 200 mg in a single oral dose (group A)
Number of subjects: 120
Study 10212779 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (CPFX) 200 mg once daily for 3 days (group B)
Number of subjects: 120
Study 10212779 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (CPFX) 200 mg twice daily for 3 days (group C)
Number of subjects: 120
Study 10212779 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpodoxime-proxcetil (CPDX-PR) 200 mg once daily for 3 days (group D)
Number of subjects: 120
Study 7786823 — intervention group
Group type: EXPERIMENTAL
Intervention: Early alternating chemotherapy (ABABAB)
Number of subjects: 406
Study 7786823 — intervention group
Group type: COMPARATOR
Intervention: Late alternating chemotherapy (AAABBB)
Number of subjects: 406
Study 7786823 — intervention group
Group type: EXPERIMENTAL
Intervention: Both early and late alternating chemotherapy
Number of subjects: 406
Study 2078039 — intervention group
Group type: EXPERIMENTAL
Intervention: Apraclonidine
Number of subjects: 0
Study 2078039 — intervention group
Group type: EXPERIMENTAL
Intervention: Apraclonidine + Pilocarpine
Number of subjects: 0
Study 2078039 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 468745 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontalis EMG biofeedback
Number of subjects: 24
Study 468745 — intervention group
Group type: EXPERIMENTAL
Intervention: Digit temperature biofeedback
Number of subjects: 24
Study 468745 — intervention group
Group type: EXPERIMENTAL
Intervention: Digit temperature biofeedback plus Rational-Emotive Therapy (RET)
Number of subjects: 24
Study 468745 — intervention group
Group type: COMPARATOR
Intervention: Self-monitoring of headache activity (waiting list)
Number of subjects: 24
Study 29316994 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/d DHA during pregnancy
Number of subjects: 98
Study 29316994 — intervention group
Group type: COMPARATOR
Intervention: Placebo during pregnancy
Number of subjects: 98
Study 29316994 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal DHA status
Number of subjects: 98
Study 29316994 — intervention group
Group type: EXPERIMENTAL
Intervention: Child DHA intake and status
Number of subjects: 98
Study 27228264 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced couple‐focused group intervention (ECG)
Number of subjects: 302
Study 27228264 — intervention group
Group type: COMPARATOR
Intervention: Couples' support group (SG)
Number of subjects: 302
Study 25370185 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) and fluoxetine
Number of subjects: 0
Study 25370185 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioural therapy (CBT) and placebo
Number of subjects: 0
Study 23033886 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium-enriched yeast (100 μg daily for 3 months)
Number of subjects: 103
Study 23033886 — intervention group
Group type: COMPARATOR
Intervention: Nonselenium-enriched yeast (control group, 3 months)
Number of subjects: 103
Study 20534755 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygonum cuspidatum extract (PCE) containing 40 mg resveratrol daily for 6 weeks
Number of subjects: 20
Study 20534755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 18674464 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 27
Study 18674464 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 27
Study 18674464 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 27
Study 18674464 — intervention group
Group type: EXPERIMENTAL
Intervention: High microemboli group
Number of subjects: 27
Study 16158720 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of tymohexine and antrale
Number of subjects: 89
Study 11961342 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (20 mg)
Number of subjects: 19
Study 11961342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 10531162 — intervention group
Group type: EXPERIMENTAL
Intervention: Grepafloxacin (GFX) 600 mg qd
Number of subjects: 504
Study 10531162 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin (CLA) 500 mg bid
Number of subjects: 504
Study 10531162 — intervention group
Group type: EXPERIMENTAL
Intervention: Grepafloxacin (GFX)
Number of subjects: 504
Study 10531162 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin (CLA)
Number of subjects: 504
Study 10531162 — intervention group
Group type: EXPERIMENTAL
Intervention: Grepafloxacin (GFX) and Clarithromycin (CLA)
Number of subjects: 504
Study 8941508 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated altitude (barometric pressure lowered to 432 +/- 2 mmHg)
Number of subjects: 9
Study 8941508 — intervention group
Group type: COMPARATOR
Intervention: Normobaric hypoxia (adding nitrogen to match inspired PO2 of altitude exposure)
Number of subjects: 9
Study 8941508 — intervention group
Group type: COMPARATOR
Intervention: Normoxic hypobaria (lowering barometric pressure and adding oxygen to match inspired PO2)
Number of subjects: 9
Study 1834144 — intervention group
Group type: EXPERIMENTAL
Intervention: Vapiprost (0.125 to 16 mg)
Number of subjects: 12
Study 1834144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7039437 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocapnic hyperventilation of cold dry air at -18 degrees C and 0% humidity
Number of subjects: 26
Study 7039437 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled methacholine
Number of subjects: 26
Study 7039437 — intervention group
Group type: COMPARATOR
Intervention: Correlation between PD10 RHE and PC20
Number of subjects: 26
Study 29974545 — intervention group
Group type: EXPERIMENTAL
Intervention: Long cyberbullying prevention program (10 weekly sessions)
Number of subjects: 722
Study 29974545 — intervention group
Group type: EXPERIMENTAL
Intervention: Short cyberbullying prevention program (one day, four sessions)
Number of subjects: 722
Study 29974545 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 722
Study 30347415 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized pedaling with martial arts (2 sessions per week for 12 weeks)
Number of subjects: 53
Study 27634489 — intervention group
Group type: EXPERIMENTAL
Intervention: Hughes Repair
Number of subjects: 800
Study 27634489 — intervention group
Group type: COMPARATOR
Intervention: Standard mass closure
Number of subjects: 800
Study 24760262 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal and stimulated C-peptide levels
Number of subjects: 582
Study 24760262 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and BMIZ
Number of subjects: 582
Study 24760262 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex
Number of subjects: 582
Study 24760262 — intervention group
Group type: COMPARATOR
Intervention: HLA type and number of positive antibodies
Number of subjects: 582